Indication
Maintenance of healing duodenal ulcer
Maintenance of healing duodenal ulcer refers to the post-acute management phase in patients who have achieved endoscopic re-epithelialization or complete resolution of an active peptic ulcer located in the proximal small intestine. Read more about Maintenance of healing duodenal ulcer
282 drugs 160 manufacturers
Drugs that treat it
Common Maintenance of healing duodenal ulcer therapies.
FAMOTIDINE
LANSOPRAZOLE
FAMOTIDINE
LANSOPRAZOLE
LANSOPRAZOLE
CIMETIDINE
FAMOTIDINE
FAMOTIDINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMaintenance of healing duodenal ulcer refers to the post-acute management phase in patients who have achieved endoscopic re-epithelialization or complete resolution of an active peptic ulcer located in the proximal small intestine.
Duodenal ulcers arise from mucosal breakdown in the duodenal bulb when aggressive factors, primarily gastric acid and pepsin, overwhelm endogenous mucosal defense mechanisms, frequently triggered by persistent *Helicobacter pylori* infection or chronic nonsteroidal anti-inflammatory drug use.
This clinical state focuses on sustained acid suppression or mucosal cytoprotection to prevent lesion recurrence and subsequent complications, such as gastrointestinal hemorrhage, perforation, or gastric outlet obstruction, particularly in individuals with recurrent ulcer disease, incomplete eradication of risk factors, or continued exposure to ulcerogenic agents.
- nih.gov
Maintenance of healing duodenal ulcer refers to the post-acute management phase in patients who have achieved endoscopic re-epithelialization or complete resolution of an active peptic ulcer located in the proximal small intestine
- fda.report
Maintenance of healing duodenal ulcer refers to the post-acute management phase in patients who have achieved endoscopic re-epithelialization or complete resolution of an active peptic ulcer located in the proximal small intestine
- nih.gov
Duodenal ulcers arise from mucosal breakdown in the duodenal bulb when aggressive factors, primarily gastric acid and pepsin, overwhelm endogenous mucosal defense mechanisms, frequently triggered by persistent *Helicobacter pylori* infection or chronic nonsteroidal anti-inflammatory drug use
- nih.gov
This clinical state focuses on sustained acid suppression or mucosal cytoprotection to prevent lesion recurrence and subsequent complications, such as gastrointestinal hemorrhage, perforation, or gastric outlet obstruction, particularly in individuals with recurrent ulcer disease, incomplete eradication of risk factors, or continued exposure to ulcerogenic agents
- nih.gov
This clinical state focuses on sustained acid suppression or mucosal cytoprotection to prevent lesion recurrence and subsequent complications, such as gastrointestinal hemorrhage, perforation, or gastric outlet obstruction, particularly in individuals with recurrent ulcer disease, incomplete eradication of risk factors, or continued exposure to ulcerogenic agents
- nih.gov
This clinical state focuses on sustained acid suppression or mucosal cytoprotection to prevent lesion recurrence and subsequent complications, such as gastrointestinal hemorrhage, perforation, or gastric outlet obstruction, particularly in individuals with recurrent ulcer disease, incomplete eradication of risk factors, or continued exposure to ulcerogenic agents
Personalize your experience
Follow Maintenance of healing duodenal ulcer and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.